Essential Medicines List Implementation Dynamics: A Case Study Using Brazilian Federal Medicines Expenditures

dc.creatorTorres, Rachel Magarinos
dc.creatorLynd, Larry David
dc.creatorLuz, Tatiana Chama Borges
dc.creatorMarques, Paulo Eduardo Potyguara Coutinho
dc.creatorCastro, Claudia Garcia Serpa Osorio de
dc.date2019-07-30T13:31:54Z
dc.date2019-07-30T13:31:54Z
dc.date2017
dc.date.accessioned2023-09-26T21:23:21Z
dc.date.available2023-09-26T21:23:21Z
dc.identifierTORRES, Rachel Magarinos et al. Essential Medicines List Implementation Dynamics: A Case Study Using Brazilian Federal Medicines Expenditures. Basic and Clinical Pharmacology and Toxicology, v. 121, p. 181-188, 2017.
dc.identifier1742-7835
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/34493
dc.identifier10.1111/bcpt.12783
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8872231
dc.descriptionThe aim was to analyse the implementation dynamics of the essential medicines list (EML). We used the government expenditures on medicines and Brazil as a case study. Drug purchases were considered as a proxy for utilization. The essential medicines (EMs) expenditures were followed over time by Brazilian National EMLs life-time and defined by broad therapeutic categories and by specific medicines. Brazil increased the number of the medicines during the last four editions of Brazilian National EMLs and the federal government expenditures on them. The EML implementation dynamics changed the distribution of expenditures on EMs. We identified a common set of 404 EMs present in all four editions of the Brazilian National EMLs. There was a proportional decrease in expenditures on anti-infectives for systemic use, blood and blood-forming organs and alimentary tract and metabolism, and increase in expenditures on antineoplastic and immunomodulating agents. The expenditures distribution per specific medicines revealed that a small set of EMs was responsible for 50% or more of expenditures considering Brazilian National EML life-time for all four periods. The increase in expenditures on EMs in Brazil was a consequence of the newer medicines incorporated over time in the Brazilian National EMLs. The use of the medicines expenditures as a source of data and the definition of an EML life-time permitted follow-up of the implementation dynamics of different versions of the Brazilian National EMLs. Our results have implications for policymakers and stakeholders to gain a better understanding of the role EMLs play in health system sustainability and in the provision of the most beneficial heath care.
dc.description2100-01-01
dc.formatapplication/pdf
dc.languageeng
dc.publisherNordic Pharmacological Society
dc.rightsrestricted access
dc.subjectEssential medicines
dc.titleEssential Medicines List Implementation Dynamics: A Case Study Using Brazilian Federal Medicines Expenditures
dc.typeArticle


Este ítem pertenece a la siguiente institución